Correlation between disease severity factors and EQ-5D utilities in chronic obstructive pulmonary disease

[1] Miravitlles M(2017)Spanish COPD Guidelines (GesEPOC) 2017. Pharmacological treatment of stable chronic obstructive pulmonary disease Archivos de Bronconeumologia 53 324-335

[2] Soler-Cataluña JJ(2005)Health-related quality of life is related to COPD disease severity Health and Quality of Life Outcomes 3 56-363

[3] Calle M(2005)Quality of life in acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease: A review of the literature Pharmacoeconomics 23 345-709

[4] Molina J(2012)Beyond FEV1 in COPD—a review of patient-reported outcomes and their measurement using a new generation of instruments The International Journal of Chronic Obstructive Pulmonary Disease 7 697-398

[5] Almagro P(2016)Health state utility value in chronic obstructive pulmonary disease (COPD); The challenge of heterogeneity: A systematic review and meta-analysis COPD 13 380-208

[6] Quintano JA(1990)EuroQol—a new facility for measurement of health related quality of life Health Policy 16 199-539

[7] Trigueros Spanish COPD(2010)Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study European Respiratory Journal 35 532-147

[8] Ståhl E(2010)A randomised controlled equivalence trial to determine the effectiveness and cost-utility of manual chest physiotherapy techniques in the management of exacerbations of chronic obstructive pulmonary disease (MATREX) Health Technology Assessment 14 1-536

[9] Lindberg A(2008)Use of a preference based measure of health (EQ-5D) in COPD and asthma Respiratory Medicine 102 519-1128

[10] Jansson SA(2006)Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages? Chest 130 1117-408

[1] Miravitlles M(2017)Spanish COPD Guidelines (GesEPOC) 2017. Pharmacological treatment of stable chronic obstructive pulmonary disease Archivos de Bronconeumologia 53 324-335

[2] Soler-Cataluña JJ(2005)Health-related quality of life is related to COPD disease severity Health and Quality of Life Outcomes 3 56-363

[3] Calle M(2005)Quality of life in acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease: A review of the literature Pharmacoeconomics 23 345-709

[4] Molina J(2012)Beyond FEV1 in COPD—a review of patient-reported outcomes and their measurement using a new generation of instruments The International Journal of Chronic Obstructive Pulmonary Disease 7 697-398

[5] Almagro P(2016)Health state utility value in chronic obstructive pulmonary disease (COPD); The challenge of heterogeneity: A systematic review and meta-analysis COPD 13 380-208

[6] Quintano JA(1990)EuroQol—a new facility for measurement of health related quality of life Health Policy 16 199-539

[7] Trigueros Spanish COPD(2010)Is treatment with ICS and LABA cost-effective for COPD? Multinational economic analysis of the TORCH study European Respiratory Journal 35 532-147

[8] Ståhl E(2010)A randomised controlled equivalence trial to determine the effectiveness and cost-utility of manual chest physiotherapy techniques in the management of exacerbations of chronic obstructive pulmonary disease (MATREX) Health Technology Assessment 14 1-536

[9] Lindberg A(2008)Use of a preference based measure of health (EQ-5D) in COPD and asthma Respiratory Medicine 102 519-1128

[10] Jansson SA(2006)Does quality of life of COPD patients as measured by the generic EuroQol five-dimension questionnaire differentiate between COPD severity stages? Chest 130 1117-408